Marketing authorisation: Splitting the bill
An increasing number of pharmaceutical companies are turning to joint representation—where they pool their funds and hire one firm to represent them all—for ANDA litigation. Mark Remus, shareholder at Brinks Gilson & Lione, outlines the pros and cons of this new direction.
- Antibody patents: Danger ahead for biologics 20-05-2019
- Warner-Lambert: the plausibility test for sufficiency of disclosure 28-11-2018
- Mexico: new links between patents and pharmaceuticals 12-11-2018
- Generic competition: when one door closes, another opens 26-10-2018
- I-MAK: saving lives by curing the patent system 19-10-2018
Latest generics news
Federal Circuit invalidates Nuvo’s Vimovo patents
17-05-2019
The US Court of Appeals for the Federal Circuit has delivered a blow to Nuvo Pharmaceuticals by reversing a decision which had upheld the validity of the Canadian company’s pain relief drug Vimovo.
EU adopts SPC manufacturing waiver
16-05-2019
E+F patent attorney elevated to partner
13-05-2019
